2025 Environmental, Social, and Governance (ESG) Report China Railway High-speed Electric Equipment Co. Ltd. 2025 中铁高铁电气装备股份有限公司 环境、社会与公司治理（ESG）报告 CONTENTS 01 报告编制说明 04 | 发布周期 | 1 | | --- | --- | | 参考依据 | 1 | | 数据说明 | 1 | | 报告承诺 | 1 | 02 关于我们 | "十四五"发展规划完成情况 | 3 | | --- | --- | | 公司简介 | 5 | | 企业使命 | 6 | | 企业愿景 | 6 | | 利益相关方沟通 | 8 | 03 董事会有关ESG情况说明 公司治理 | 党的领导 | 9 | | --- | --- | | 股东会 | 10 | | 董事会 | 11 | | 监事会改革 | 11 | | 反腐倡廉 | 12 | | 05 | | --- | | 社会责任 | | 创新发展 | 20 | | --- | --- | | 员工权益保障 | 28 | | 保障员工健 ...

证券代码：688285 证券简称：高铁电气 公告编号：2026-005 中铁高铁电气装备股份有限公司 关于公司 2025 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每 10 股派发现金红利 0.13 元（含税），不进行资本公积 金转增股本，不送红股。 本次利润分配以实施权益分派股权登记日登记的总股本为 基数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟 维持分配总额不变，相应调整每股分配比例，并将另行公告具体调整 情况。 公司未触及《上海证券交易所科创板股票上市规则》（以下 简称"《科创板股票上市规则》"）第 12.9.1 条第一款第（八）项 规定的可能被实施其他风险警示的情形。 一、 利润分配方案内容 （一）2025年年度现金分红 －1－ 会第十四次会议审议通过，公司拟以实施权益分派股权登记日登记的 总股本为基数分配利润，2025 年度利润分配方案如下： 以截至 2025 年 12 月 31 日的公司总股本 376,289,913.0 ...

中铁高铁电气装备股份有限公司2025 年年度报告 公司代码：688285 公司简称：高铁电气 中铁高铁电气装备股份有限公司 2025 年年度报告 1 / 244 中铁高铁电气装备股份有限公司2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司上市时未盈利且尚未实现盈利 □是 √否 三、重大风险提示 公司可能存在的风险已在本报告中"第三节 管理层讨论与分析"中详细描述，敬请投资者注意 投资风险。 四、公司全体董事出席董事会会议。 五、 中审众环会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 六、公司负责人张厂育、主管会计工作负责人王徐策及会计机构负责人（会计主管人员）张亚军 声明：保证年度报告中财务报告的真实、准确、完整。 七、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经公司研究，提出利润分配方案如下：以实施权益分派股权登记日登记的总股本为基数，向 全体股东每10股派发现金红利0.13元（含税），不进行资本公积转增股本，不送红股。以截至2 ...

中铁高铁电气装备股份有限公司 董事、高级管理人员薪酬管理制度 第一章 总则 第一条 为规范中铁高铁电气装备股份有限公司（以下 简称"公司"）董事、高级管理人员薪酬管理体系，建立合 理有效的企业激励约束机制，提升经营管理效益，根据《中 华人民共和国公司法》《上市公司治理准则》等法规和规范 性文件以及《中铁高铁电气装备股份有限公司章程》（以下 简称"《公司章程》"）的规定，结合公司实际情况，制定 本制度。 第二条 本制度的适用对象包括以下人员： （一）公司全体董事，包括非独立董事和独立董事。非 独立董事包括内部董事和外部董事，内部董事指在公司任职 的董事，外部董事指不在公司任职的非独立董事。 （二）公司高级管理人员，包括公司总经理、副总经理、 总会计师、董事会秘书和总工程师、总经济师、总经理助理 和《公司章程》规定的其他人员。 第三条 公司董事和高级管理人员的薪酬分配遵循以下 原则： （二）责权利对等原则：薪酬与岗位价值高低、承担责 任大小相符； （三）激励与约束并重原则：体现薪酬发放与考核、奖 罚、激励机制挂钩； （四）长远发展原则：与公司长远利益、持续健康发展 的目标相符。 第二章 管理机构 第四条 公司董事 ...

Core Viewpoint - The company reported a preliminary performance summary for the fiscal year 2025, indicating a positive growth trajectory in both revenue and net profit [1][2]. Financial Performance - The total operating revenue for the company reached 1.181 billion yuan, representing a year-on-year increase of 17.16% [1]. - The net profit attributable to the parent company's shareholders was 51.4615 million yuan, showing a year-on-year growth of 14.02% [1]. Market Dynamics - Recent market activity indicates a net inflow of principal funds into the company [3].

Financial Performance - In 2025, the company achieved operating revenue of 118,110.55 million RMB, representing a year-on-year increase of 17.16% [1] - The net profit attributable to the parent company was 5,146.15 million RMB, up 14.02% compared to the previous year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 4,363.46 million RMB, reflecting a growth of 9.29% year-on-year [1] - Basic earnings per share were 0.1368 RMB, an increase of 14.10% from the previous year [1] Financial Position - As of the end of 2025, the company's total assets amounted to 313,402.29 million RMB, a growth of 1.91% from the end of the previous year [2] - The equity attributable to the parent company reached 169,007.50 million RMB, which is a 2.67% increase year-on-year [2] - The net asset value per share attributable to the parent company was 4.49 RMB, up 2.75% from the previous year [2] Profitability Improvement - Operating profit increased by 39.58% year-on-year, with total profit also rising by 39.58%, primarily due to the increase in operating revenue and the company's focus on lean production and management [3]

Core Viewpoint - The company announced a projected revenue of 1,181.11 million yuan for 2025, representing a year-on-year growth of 17.16% and a net profit attributable to the parent company of 51.46 million yuan, reflecting a 14.02% increase year-on-year [1] Financial Performance - Projected revenue for 2025 is 1,181.11 million yuan, which is an increase of 17.16% compared to the previous year [1] - Net profit attributable to the parent company is expected to reach 51.46 million yuan, marking a year-on-year growth of 14.02% [1]

Investment Projects - Huangshan Tourism plans to invest approximately 530 million yuan in the construction of the Huangshan Binjiang East Road No. 12 hotel project, with a total construction area of 79,178.15 square meters and a construction period of 24 months [2] - Xuguang Electronics intends to raise no more than 1 billion yuan through a private placement to fund projects including the expansion of high-voltage vacuum arc extinguishing chambers and other R&D initiatives [4] - Jichuan Pharmaceutical's subsidiary has paid 80 million yuan for exclusive commercialization rights of the Inusimab injection, indicating a strategic move into the biopharmaceutical market [5] Stock Performance and Risks - Hangdian Co. reported a significant stock price increase of 32.97% over three trading days, but warns of potential trading risks due to a negative rolling P/E ratio and expected net loss of approximately 300 million yuan for 2025 [3] - Sanbian Technology and Tiantong Co. both experienced abnormal stock price fluctuations, with no undisclosed significant information affecting their operations [6][7] - Wanfeng Co. noted a stock price increase of 46.43% while highlighting uncertainties regarding the price changes of core intermediate products and their impact on future earnings [8] Financial Performance - Gaotie Electric reported a net profit of 51.46 million yuan for 2025, a year-on-year increase of 14.02%, with total revenue of 1.181 billion yuan, up 17.16% [10] - Yaokang Bio achieved a net profit of 144.40 million yuan, reflecting a 31.49% increase year-on-year, driven by improved overseas sales and domestic demand recovery [11] - Babi Foods reported a slight decline in net profit to 273 million yuan, despite a revenue increase of 11.22% to 1.859 billion yuan, indicating challenges in maintaining profitability [12] - Zhongyuan Media's net profit rose by 30.99% to 1.349 billion yuan, despite a revenue decline of 5.13% [13] Shareholding Changes - Shangluo Electronics' controlling shareholder plans to reduce their stake by 3% due to personal financial needs [15] - Yilian Technology's shareholder intends to reduce their holdings by up to 2% within three months [16] - Wuxi Zhenhua's shareholders plan to reduce their stakes by 2% and 1% respectively [17] - Changchun Yidong's shareholder intends to reduce their stake by 3% through various trading methods [18] Major Contracts - Yitong Century has been pre-selected for a 1.07 billion yuan comprehensive maintenance service project with China Tower [20] - Chengbang Co. signed new project contracts worth 40.03 million yuan in Q4 2025, contributing to a total of 1.43 billion yuan for the year [21] - Hongfuhan signed a contract worth 480 million yuan with Guangdong Quanxiang for the supply of robots and related products, which is expected to significantly impact future earnings [22]

Group 1 - Fulin Precision's subsidiary Jiangxi Shenghua invested 270 million yuan to establish a joint venture for a 500,000-ton ferrous oxalate project, with a total investment of 1.5 billion yuan expected to be completed by September 30, 2026 [1] - Xuguang Electronics plans to raise up to 1 billion yuan through a private placement to fund high-voltage vacuum arc extinguishing chamber expansion and other projects [2] - Minexplosion Optoelectronics intends to acquire 100% equity of Xiazhi Precision, with the transaction subject to shareholder and regulatory approvals [3] Group 2 - Shangluo Electronics' controlling shareholder plans to reduce his stake by up to 3% due to personal financial needs [4] - Babi Food reported a 1.3% decline in net profit for 2025, despite an 11.22% increase in revenue [5] - Pengding Holdings' subsidiary acquired industrial land in Huai'an for 66.14 million yuan [6] Group 3 - Zhuoyue New Energy's net profit for 2025 increased by 14.16%, despite a 17.43% decline in revenue [7] - Zhongyuan Media's net profit grew by 30.99% in 2025, with revenue decreasing by 5.13% [8] - Huangshan Tourism plans to invest approximately 530 million yuan in a hotel project with a 24-month construction period [9] Group 4 - *ST Jinling's restructuring plan was approved by the court, which may improve the company's financial situation [11] - Jichuan Pharmaceutical's subsidiary paid 80 million yuan for exclusive commercialization rights of a drug [12] - Pilin Bio's subsidiary received a notice for the acceptance of a drug supplement application [13] Group 5 - Nepe Mining terminated its investment in Swiss Veritas Resources AG due to changes in conditions [14] - Jinhui Wine announced a cash dividend of 0.20 yuan per share for the first three quarters of 2025 [15] - Hualan Biological's clinical trial for a new drug received approval for an additional indication [16] Group 6 - Industrial Fulian reported a total of 247 million yuan spent on share buybacks as of January 31, 2026 [17] - Yitong Century was pre-selected for a 107 million yuan project with China Tower [18] - Wanfeng Co. noted uncertainty in future price changes for disperse dyes [19] Group 7 - Bibet's clinical trial application for a new drug was approved by the National Medical Products Administration [21] - Chengbang Co. signed new project contracts worth 40.03 million yuan in Q4 2025 [22] - *ST Hengji received a court ruling for a performance compensation of 175 million yuan [23] Group 8 - Jihua Group is planning a change in control, leading to continued stock suspension [24] - Ningbo Port expects a container throughput of 5.03 million TEUs in January 2026, a 9.5% increase [25] - Hengli Petrochemical's actual controller increased his stake by 3.3 million shares [26] Group 9 - Hongfuhan signed a sales contract worth 480 million yuan with Guangdong Quanxiang [27] - All New Good's shareholder lifted a judicial freeze on 4.36% of the company's shares [28] - Changchun High-tech's subsidiary's clinical trial application for a new drug was accepted [29] Group 10 - Xingqi Eye Medicine's clinical trial for a new drug entered the first/second phase [31] - Hanma Technology reported a 140.04% increase in new energy heavy truck production in January 2026 [32] - Hengfeng Paper plans to invest 349 million yuan in a new green printing project [33] Group 11 - Zhifei Biological's mRNA vaccine for shingles received clinical trial approval [34] - Yutong Bus reported a 15.35% decrease in production in January 2026 [35] - StarNet Ruijie plans to sign a lease contract with an affiliate for a total rent of up to 110 million yuan [36] Group 12 - Hacheng Bonda's director completed a 0.97% share reduction [37] - Hendi Pharmaceutical's application for a new drug was approved [38] - Xinhua Medical's subsidiary received a medical device registration certificate [40] Group 13 - Yaokang Bio reported a 31.49% increase in net profit for 2025 [41] - Gaotie Electric reported a 14.02% increase in net profit for 2025 [42]

格隆汇2月3日丨高铁电气(688285.SH)公布2025年度业绩快报，2025年公司实现营业收入11.81亿元，较 上年同期增长17.16%；实现归属于母公司所有者的净利润5146.15万元，较上年同期增长14.02%；实现 归属于母公司所有者的扣除非经常性损益的净利润4363.46万元，较上年同期增长9.29%；基本每股收益 0.1368元，较上年同期增长14.10%。 营业利润较上年同期增长39.58%，利润总额同比增长39.58%，主要原因系2025年营业收入较上年提 升，同时公司继续专注于精益生产和管理，相关利润指标较上年增长。 ...